hantavirus
hv
rodenttransmit
virus
caus
hantaviru
cardiopulmonari
syndrom
hcp
america
hemorrhag
fever
renal
syndrom
hfr
eurasia
togeth
virus
annual
caus
approxim
human
infect
worldwid
recent
year
case
fatal
rate
hfr
hcp
current
effect
treatment
avail
either
hfr
hcp
whole
viru
inactiv
vaccin
htnv
seov
licens
use
republ
korea
china
protect
efficaci
vaccin
uncertain
larg
extent
immun
correl
protect
hantaviru
known
review
summar
epidemiolog
virolog
pathogenesi
four
hfrscaus
virus
htnv
seov
puuv
dobv
two
hcpscaus
virus
andv
snv
discuss
exist
knowledg
vaccin
therapeut
diseas
think
inform
shed
light
ration
develop
new
vaccin
treatment
recent
year
repeat
outbreak
hantaviru
diseas
caus
seriou
threat
human
health
spread
hantaviru
natur
host
human
natur
ecolog
process
howev
outbreak
hantaviru
driven
stripe
field
mous
popul
cycl
dynam
season
climat
chang
tian
stenseth
hantaviru
viru
transmit
mainli
rodent
anim
mainli
urin
fece
saliva
aerosol
produc
rare
bite
infect
anim
brocato
hooper
recent
year
infect
rate
hantaviru
increas
china
europ
dong
et
al
hantaviru
diseas
turn
newli
identifi
new
diseas
germani
kruger
et
al
clinic
present
may
vari
accord
viral
strain
preval
differ
region
asia
hantaviru
infect
hantan
viru
htnv
seoul
viru
seov
target
mainli
human
kidney
caus
hemorrhag
fever
renal
syndrom
hfr
north
america
infect
and
viru
andv
sin
nombr
viru
snv
manifest
mainli
lung
lead
hantaviru
pulmonari
syndrom
hp
hantaviru
cardiopulmonari
syndrom
hcp
high
mortal
rate
europ
infect
puumala
viru
puuv
dobravabelgrad
viru
dobv
typic
caus
milder
form
hfr
nephropathia
epidemica
ne
echterdiek
et
al
current
approv
postexposur
therapeut
countermeasur
hantavir
infect
diversifi
treatment
strategi
develop
appli
manag
hfr
hcp
strategi
target
viral
life
cycl
host
immunolog
factor
patient
clinic
symptom
prevent
measur
hantavir
infect
especi
vaccin
develop
essenti
futur
pandem
paper
review
epidemiolog
pathogenesi
hantaviru
discuss
exist
knowledg
vaccin
therapeut
diseas
order
shed
light
develop
new
vaccin
treatment
china
highest
incid
mortal
hfr
world
account
total
number
hfr
case
world
zheng
et
al
chines
center
diseas
control
prevent
china
cdc
establish
nation
notifi
diseas
surveil
system
nndss
onlin
hfr
case
whole
countri
report
daili
system
zhang
et
al
total
case
death
report
averag
annual
incid
rate
per
mortal
rate
per
case
fatal
rate
zhang
et
al
main
caus
pathogen
htnv
seov
tian
stenseth
far
hfr
case
report
provinc
china
exclud
hong
kong
macao
taiwan
zhang
et
al
recent
year
incid
still
high
eastern
china
tian
et
al
distribut
map
hantaviru
case
report
recent
chines
literatur
summar
figur
total
case
cluster
nine
provinc
mainli
report
spring
autumnwint
season
observ
annual
averag
number
case
shaanxi
provinc
higher
rank
top
list
figur
shaanxi
gradual
becom
provinc
highest
incid
china
approxim
case
concentr
central
region
xian
xianyang
baoji
weinan
citi
zheng
et
al
novemb
peopl
record
infect
shaanxi
provinc
dong
et
al
also
observ
averag
annual
number
case
citi
shannxi
shandong
jiangxi
provinc
rank
top
three
supplementari
figur
anoth
place
high
incid
hfr
qingdao
citi
shandong
provinc
hfr
incid
three
time
higher
nation
averag
reach
jiang
et
al
us
state
confirm
record
hcp
case
sinc
princ
lieberman
first
local
acquir
case
hfr
caus
seov
confirm
us
cdc
investig
outbreak
seov
infect
infect
rat
owner
seven
state
kerin
et
al
number
hantaviru
case
year
differ
state
summar
figur
canada
hcp
still
rare
case
record
everi
year
show
season
pattern
mainli
march
may
septemb
novemb
total
case
confirm
sinc
report
western
canadian
provinc
alberta
manitoba
british
columbia
saskatchewan
kerin
et
al
snv
andv
respons
major
hantaviru
case
lead
hcp
outsid
north
america
individu
case
small
cluster
hcp
report
balkan
northern
sweden
bergstedt
oscarsson
et
al
argentina
pini
et
al
chile
toro
et
al
poland
gut
et
al
bolivia
brazil
suzuki
et
al
limongi
et
al
serbia
stanojev
et
al
unit
kingdom
duggan
panama
bayard
et
al
germani
etting
et
al
overal
europ
incid
hantaviru
infect
steadili
increas
recent
year
record
number
infect
regist
across
europ
chile
averag
case
per
year
sinc
diseas
occur
mainli
spring
summer
howev
june
octob
increas
case
rodent
popul
toro
et
al
paraguay
hcp
case
first
found
chako
region
total
case
report
case
report
padula
et
al
panama
hcp
first
appear
averag
patient
per
year
howev
case
report
case
confirm
august
first
time
sinc
uruguay
experienc
hcp
case
averag
nine
case
per
year
first
case
record
northern
uruguay
poland
infect
caus
mainli
puuv
dobv
serotyp
morbid
high
rang
per
case
paper
suggest
data
concern
poland
underestim
gut
et
al
number
infect
higher
like
epidem
year
follow
year
infect
case
regist
respect
germani
incid
increas
etting
et
al
unit
kingdom
viru
first
identifi
laboratori
rat
scotland
case
seov
caus
acut
kidney
injuri
diagnos
rare
import
pathogen
laboratori
duggan
hantavirus
belong
famili
hantavirida
bunyaviral
kind
envelop
singl
neg
chain
rna
viru
abudurex
et
al
maximum
likelihood
phylogenet
tree
complet
amino
acid
cd
sequenc
segment
hantavirus
made
base
intern
committe
taxonomi
virus
ictv
updat
taxonomi
order
bunyaviral
see
figur
phylogeni
show
modest
genet
divers
viru
famili
diamet
hantaviru
particl
nm
structur
spheric
ovoid
compos
fat
protein
carbohydr
rna
stabl
surviv
day
c
c
day
room
temperatur
genom
compris
three
neg
sens
singlestrand
rna
consist
small
medium
larg
l
segment
encod
nucleoprotein
np
envelop
glycoprotein
gn
gc
viral
rnadepend
rna
polymeras
rdrp
respect
graham
et
al
outer
membran
hantaviru
compos
gn
gc
glycoprotein
mediat
recognit
entri
host
cell
crystal
structur
htnv
gn
similar
puuv
gn
confirm
hantaviru
gn
conserv
hantaviru
li
et
al
rissanen
et
al
although
substanti
vaccin
licens
vaccin
hantaviru
infect
wide
use
despit
inactiv
hantaviru
vaccin
licens
human
use
china
korea
vaccin
approv
us
europ
tian
stenseth
current
clinic
studi
inactiv
hantaviru
vaccin
china
korea
clinic
trial
dna
vaccin
us
summar
tabl
inactiv
vaccin
compris
entir
virion
inactiv
physic
heat
chemic
korea
lee
cho
et
al
first
develop
inactiv
htnv
vaccin
ihv
prepar
htnv
strain
rok
prolifer
brain
lactat
mice
proven
induc
protein
immun
mice
human
yamanishi
et
al
korean
hfr
vaccin
hantavax
put
commerci
product
total
number
hfr
patient
hospit
south
korea
fell
sharpli
cho
et
al
evalu
immunogen
safeti
hantavax
tm
healthi
adult
multicent
phase
iii
clinic
trial
three
dose
schedul
month
use
seroconvers
rate
ifa
two
primari
dose
one
month
vaccin
posit
rate
serum
accord
ifa
respect
neutral
antibodi
respons
two
initi
dose
hantavax
tm
poor
therefor
necessari
carri
enhanc
immun
within
month
provid
time
protect
highrisk
group
song
et
al
januari
februari
south
korean
militari
conduct
casecontrol
studi
patient
evalu
effect
ihv
hfr
vaccin
effect
valu
ihv
valu
hfr
highincid
area
higher
howev
efficaci
ihv
progress
hfr
show
statist
signific
protect
effect
patient
inocul
hfr
vaccin
patient
vaccin
hfr
vaccin
recruit
korean
armi
hospit
investig
sever
aki
efficaci
dialysi
event
acut
renal
injuri
overal
effect
vaccin
group
three
stage
aki
compar
nonvaccin
group
cur
effect
ihv
diseas
progress
cur
effect
ihv
hfr
progress
show
statist
signific
protect
effect
yi
et
al
china
bival
inactiv
vaccin
htnv
seov
infect
produc
approv
pharmacopoeia
china
sinc
chines
govern
implement
expand
immun
program
target
hfr
china
use
approxim
million
dose
hfr
vaccin
everi
year
schmaljohn
hfr
case
significantli
drop
less
per
year
phase
clinic
trial
inactiv
hantaviru
vaccin
show
median
od
valu
igg
antibodi
posit
rate
prevaccin
month
two
primari
dose
booster
dose
month
booster
dose
respect
although
two
main
dose
help
healthi
individu
develop
immun
respons
threedos
seri
better
twodos
seri
zheng
et
al
anoth
clinic
studi
xian
yang
citi
northwest
china
show
posit
rate
neutral
antibodi
unvaccin
group
posit
rate
respect
month
immun
vaccin
consist
mixtur
inactiv
htnv
seov
find
indic
vaccin
program
induc
effect
humor
immun
northwestern
china
maintain
month
vaccin
tabl
present
dna
vaccin
popular
method
research
hfr
hcp
vaccin
mainli
focus
use
heteroexpress
system
produc
recombin
protein
dna
vaccin
character
safeti
replic
defect
restor
virul
spread
person
person
environ
varieti
dna
vaccin
hantaviru
envelop
glycoprotein
gene
develop
hopper
group
schmaljohn
et
al
figur
hantaviru
phylogenet
tree
basi
segment
sequenc
maximum
clade
credibl
tree
complet
amino
acid
sequenc
protein
encod
segment
virus
belong
hantaviru
differ
color
repres
differ
clade
protein
high
similar
signatur
domain
highli
unconserv
termin
sequenc
could
artifici
creat
similar
sequenc
align
properli
made
therefor
phylogenet
tree
made
robust
method
use
tcoffe
default
paramet
remov
unconserv
site
filter
column
score
multipl
sequenc
align
smsphyml
default
paramet
bootstrap
best
model
lg
g
ml
maximum
likelihood
tree
construct
studi
confirm
dna
vaccin
produc
neutral
antibodi
multipl
experiment
anim
speci
protect
hamster
hfr
schmaljohn
et
al
next
develop
hfr
candid
dna
vaccin
express
htnv
puuv
gn
gc
gene
evalu
openlabel
singlecent
phase
studi
result
show
htnv
puuv
dna
vaccin
prepar
electropor
safe
mix
togeth
respons
puuv
greater
htnv
dna
vaccin
dna
vaccin
immunogen
vaccin
enter
phase
trial
compar
immun
respons
two
differ
dose
mg
mix
htnv
puuv
dna
vaccin
healthi
particip
group
also
receiv
booster
dose
month
first
vaccin
determin
dose
vaccin
plan
best
way
advanc
vaccin
develop
process
evalu
safeti
respons
immunogen
andv
dna
vaccin
prevent
hp
first
phase
clinic
trial
andv
dna
vaccin
began
februari
tabl
similarli
dna
vaccin
develop
hantaviru
target
gene
express
envelop
gp
gn
gc
hantavirus
tabl
part
unit
state
varieti
dna
vaccin
express
envelop
glycoprotein
gene
hantavirus
develop
hopper
group
schmaljohn
et
al
hfr
candid
nake
dna
vaccin
construct
subclon
method
subclon
cdna
repres
medium
fragment
yield
nucleocapsid
protein
rang
mg
per
g
wet
weight
yeast
cell
razanskien
et
al
continu
frontier
microbiolog
wwwfrontiersinorg
encod
g
g
glycoprotein
small
fragment
encod
nucleocapsid
protein
seov
clone
express
vector
wrg
syrian
hamster
vaccin
vaccin
gene
gun
hantavirusspecif
antibodi
found
hamster
hamster
respect
evid
infect
monitor
challeng
seov
twentyeight
day
later
hamster
vaccin
protect
hamster
infect
inocul
protect
hooper
et
al
htnv
gene
product
g
g
express
nonhuman
primat
evalu
htnv
gene
protect
effect
htnv
seov
dobv
hamster
htnv
andv
gene
induc
high
level
neutral
antibodi
rhesu
monkey
hooper
et
al
next
dna
vaccin
plasmid
contain
fulllength
genom
fragment
andv
pwrgandm
construct
rhesu
monkey
inocul
pwrgandm
gene
gun
produc
high
level
neutral
antibodi
neutral
andv
also
hcpsrelat
hantaviru
strain
snv
day
inject
monkey
serum
protect
hamster
fatal
diseas
custer
et
al
pwrgham
plasmid
contain
htnv
andv
gene
fragment
construct
rhesu
monkey
immun
pwrgham
vaccin
produc
antibodi
bind
gene
product
g
g
glycoprotein
neutral
htnv
andv
subsequ
year
initi
vaccin
seri
neutral
antibodi
titer
induc
doubl
immunogen
pwrgham
singl
immunogen
express
htnv
andv
gp
increas
rapidli
high
level
result
first
time
hantaviru
gene
dna
vaccin
shown
elicit
strong
memori
respons
stimul
antibodi
respons
neutral
hfr
hcp
virus
hooper
et
al
kwila
et
al
detect
hightit
neutral
antibodi
induc
snvandv
dna
vaccin
encod
viral
envelop
gp
laboratori
anim
nonhuman
primat
nhcp
deliv
effect
use
dispos
syring
inject
dsji
system
kwila
et
al
brocato
et
al
clone
codonoptim
puuv
fragment
dna
vaccin
vector
produc
plasmid
pwrgpuum
produc
hightit
neutral
antibodi
hamster
nhcp
pwrgpuum
vaccin
protect
hamster
puuv
infect
affect
dobv
infect
unexpectedli
vaccin
could
protect
hamster
absenc
andv
crossneutr
antibodi
lethal
andv
diseas
model
author
tri
produc
panhantaviru
vaccin
mix
plasmid
dna
vaccin
studi
andv
hamster
model
show
neutral
antibodi
produc
dna
vaccin
technolog
use
resist
challeng
snv
fulllength
gene
dna
vaccin
prevent
occurr
hcp
rabbit
vaccin
snv
dna
vaccin
muscl
electropor
mep
produc
increas
neutral
antibodi
titer
addit
hamster
vaccin
three
time
snv
dna
vaccin
gene
gun
complet
free
snv
infect
rabbit
vaccin
hcp
mixtur
andv
snv
plasmid
hfr
mix
htnv
puuv
plasmid
hcpshfr
mixtur
four
plasmid
mep
result
show
hcp
mixtur
hfr
mixtur
produc
neutral
antibodi
andvsnv
htnvpuuv
respect
addit
mixtur
hcpshfr
trigger
neutral
antibodi
four
virus
spik
et
al
report
puuv
htnv
dna
vaccin
serv
separ
regul
vaccin
produc
neutral
antibodi
inject
alon
administ
mixtur
one
two
hantaviru
antibodi
could
detect
contrast
dna
administ
anim
separ
vaccin
reaction
observ
improv
use
dna
vaccin
multihead
intraderm
electropor
devic
develop
use
vaccin
increas
dose
dna
vaccin
skin
devic
enabl
multiplasmid
vaccin
prepar
provid
multiplasmid
vaccin
prepar
without
interfer
mackow
et
al
china
dna
vaccin
target
hantaviru
gn
merg
antigen
lysosomeassoci
membran
protein
lamp
therebi
chang
antigen
present
pathway
activ
cell
lamp
target
strategi
success
enhanc
effect
htnv
gn
vaccin
studi
show
pvaxlampgn
establish
memori
respons
longterm
protect
month
mice
zhao
et
al
construct
multiepitop
chimer
dna
vaccinenam
shp
chimer
gene
contain
glycoprotein
epitop
seov
htnv
puuv
humor
cellular
respons
significantli
enhanc
vaccin
balbc
mice
zhao
et
al
subunit
protein
vaccin
safe
easi
produc
also
easili
caus
interfer
compon
multival
formul
liang
et
al
qu
et
al
n
protein
hantaviru
circul
differ
contin
provid
high
crossprotect
anim
n
protein
consid
import
part
wide
rang
reactiv
vaccin
hantaviru
infect
de
carvalho
nicacio
et
al
research
shown
recombin
nucleocapsid
protein
rn
puuv
topv
andv
dobv
could
induc
crossprotect
immun
respons
puuv
crossreact
puuv
antigen
highest
serum
anim
immun
andv
rn
follow
topv
dobv
rn
prolifer
test
lymphocyt
immun
heterogen
rn
effect
recal
puuv
rn
vitro
anim
lymphocyt
immun
homolog
protein
de
carvalho
nicacio
et
al
addit
recombin
vaccinia
viru
carri
puuv
n
first
half
gene
construct
detect
clone
puuvspecif
ctl
pbmc
patient
ne
recombin
puuv
vaccinia
viru
led
isol
ctl
cell
line
recogn
protein
epitop
determin
terajima
et
al
razanskien
et
al
report
stabil
high
puriti
np
puuv
dobv
htnv
rang
mgg
wet
weight
yeast
cell
dobv
rn
protein
promis
vaccin
candid
protein
induc
nspecif
antibodi
termin
titer
high
mice
antibodi
induc
dobv
rn
protein
high
crossreact
rn
protein
puuv
htnv
found
might
rna
fragment
exchang
two
puuv
strain
nlink
glycosyl
occur
one
site
gn
n
gc
n
possibl
oglycosyl
site
identifi
gc
studi
code
gene
product
great
signific
design
new
vaccin
johansson
et
al
schmidt
et
al
report
np
seov
react
seovspecif
monoclon
antibodi
htnvand
puuv
crossreact
monoclon
antibodi
rabbit
immun
recombin
np
induc
hightit
antibodi
respons
npspecif
antibodi
detect
serum
experiment
infect
rat
human
expos
hantaviru
differ
geograph
sourc
yeastexpress
seov
n
protein
repres
promis
antigen
serolog
epidemiolog
research
vaccin
develop
schmidt
et
al
antoniuka
et
al
report
biomass
express
level
recombin
puuv
np
increas
ad
plant
extract
ynb
medium
maximum
volum
yield
n
protein
mg
l
antoniuka
et
al
tabl
part
viruslik
particl
vaccin
similar
natur
viru
particl
lack
infecti
genet
materi
compos
repetit
viral
structur
protein
inher
selfassembl
characterist
yong
et
al
improv
immunogen
vlp
import
report
either
gmcsfcontain
htnv
vlp
express
insect
cell
cho
cell
ying
et
al
could
enhanc
activ
macrophag
dendrit
cell
incorpor
vlp
induc
elev
level
htnvspecif
antibodi
neutral
antibodi
mice
spleen
cell
immun
mice
enhanc
abil
secret
increas
ctl
activ
gmcsf
vlp
express
eukaryot
express
vector
stabl
longterm
protect
effect
high
titer
neutral
antibodi
mice
within
month
immun
dong
et
al
result
suggest
vlp
use
potenti
candid
vaccin
hantavirus
primarili
infect
host
capillari
endotheli
cell
variou
organ
especi
kidney
lung
could
spark
robust
immun
respons
human
basic
patholog
featur
old
world
hantavirus
caus
hfr
new
world
hantavirus
lead
hcp
dramat
increas
vascular
permeabl
pathogenesi
highli
involv
viral
infect
excess
immun
respons
host
extens
capillari
leakag
result
multipl
clinic
manifest
hypotens
shock
hfr
noncardiogen
pulmonari
edema
hcp
might
deterior
multisystem
organ
failur
current
approv
postexposur
therapeut
countermeasur
hantavir
infect
diversifi
treatment
strategi
target
viral
life
cycl
host
immunolog
factor
patient
clinic
symptom
develop
appli
manag
hfr
hcp
see
tabl
virustarget
antivir
includ
classic
antivir
drug
antibodi
novel
small
molecul
test
mainli
block
hantaviru
entri
restrain
viru
replic
although
sever
antivir
proven
protect
vitro
vivo
still
exist
problem
clinic
applic
hosttarget
medicin
design
improv
vascular
function
rebuild
immun
homeostasi
cur
effect
still
debat
support
care
univers
appli
hfr
hcp
specif
treatment
depend
clinic
find
differ
diseas
phase
viral
entri
process
compos
viru
attach
absorpt
suscept
cell
penetr
subsequ
uncoat
first
step
hantavir
life
cycl
neutral
antibodi
nab
could
interact
viral
envelop
protein
disturb
bind
receptor
host
cell
thu
block
viral
attach
hantaviru
infect
gn
gc
glycoprotein
nucleocapsid
protein
np
consid
major
antigen
induc
nab
product
jiang
et
al
high
level
nab
could
detect
convalesc
phase
hfr
hcp
patient
nab
could
protect
individu
hantavir
infect
use
passiv
immunotherapi
manigold
vial
jiang
et
al
present
report
clinic
random
control
trial
use
nab
immunotherapi
hfr
hcp
human
studi
measur
antibodi
efficaci
focu
reduct
neutral
test
frnt
hemagglutin
inhibit
hi
test
cellular
level
well
anim
experi
lethal
hantaviru
challeng
suck
mice
newborn
rat
model
htnv
seov
infect
hamster
model
andv
snv
infect
zhang
et
al
xu
et
al
manigold
vial
old
world
hantavirus
crude
fab
prepar
direct
puuv
gc
protein
gener
splenic
lymphocyt
puuvimmun
individu
exhibit
typespecif
neutral
puuv
reduct
frnt
de
carvalho
nicacio
et
al
seov
rat
serum
appli
h
h
challeng
could
protect
lethal
seov
infect
newborn
rat
crossprotect
effect
also
found
seov
htnv
zhang
et
al
china
murin
monoclon
antibodi
mab
target
htnv
prepar
lab
among
target
np
react
gc
recogn
np
gc
gcrelat
mab
activ
hi
test
display
high
virusneutr
activ
vitro
could
regard
htnv
nab
consist
administr
nab
within
hpi
could
protect
suckl
mice
lethal
htnv
infect
indic
nab
might
potenti
treatment
strategi
preexposur
prophylaxi
postexposur
therapi
htnv
infect
xu
et
al
phase
clinic
pharmacolog
toxic
test
htnv
nab
healthi
volunt
perform
phase
ii
clinic
trial
assess
therapeut
efficaci
nab
earli
stage
hfr
carri
endem
set
china
xu
et
al
xu
et
al
new
world
hantavirus
passiv
immun
either
patientderiv
vaccineinduc
nab
capabl
protect
lethal
andv
challeng
hamster
manigold
vial
nonrandom
multicent
trial
use
plasma
hcp
convalesc
patient
treatment
acut
hcp
carri
chile
show
plasma
contain
high
titer
nab
andv
could
significantli
reduc
case
fatal
rate
vial
et
al
consid
limit
avail
convalesc
plasma
hcp
survivor
goos
polyclon
antibodi
acquir
andv
dna
vaccin
purifi
igyigi
fc
egg
yolk
could
protect
hamster
lethal
andv
infect
recent
two
nab
develop
andv
gpspecif
memori
b
cell
convalesc
hcp
patient
reach
protect
rate
lethal
andv
challeng
garrido
et
al
although
nab
convalesc
patient
immun
anim
could
obvious
restrain
hantavir
infect
improv
diseas
outcom
purifi
human
human
nab
hantavirus
increas
secur
efficaci
develop
clinic
experi
addit
research
broadli
neutral
antibodi
hantavirus
still
lack
hantavir
attach
absorpt
could
also
restrain
lactoferin
lf
ironbind
glycoprotein
report
broad
antibacteri
antifung
antivir
activ
lfpretreat
vero
cell
show
reduc
number
seov
foci
antivir
effect
obvious
compromis
lfpretreat
cell
monolay
wash
seov
infect
murphi
et
al
lf
could
suppress
viral
shed
within
hpi
effect
fail
hpi
murphi
et
al
result
indic
lf
might
adher
cell
surfac
inhibit
seov
adsorpt
host
cell
intriguingli
although
lf
could
inhibit
express
np
gc
hantavir
amplif
establish
cell
lf
contribut
higher
surviv
rate
might
due
lfenhanc
cytocid
function
natur
killer
nk
cell
murphi
et
al
even
specif
mechan
lf
inhibit
seov
absorpt
influenc
host
immun
respons
well
effect
lf
speci
hantavirus
remain
obscur
hantavir
fusion
cell
membran
facilit
entri
process
hantaviru
gc
envelop
glycoprotein
act
viral
fusion
protein
essenti
viral
entri
demonstr
gc
share
similar
featur
class
ii
fusion
protein
mean
three
domain
viral
fusion
protein
connect
stem
region
anchor
viral
envelop
cifuentesmunoz
et
al
exogen
protein
fragment
contain
fusion
protein
domain
iii
diii
stem
region
could
bind
core
fusion
protein
interfer
conform
transit
inhibit
membran
fusion
process
base
effect
solubl
recombin
peptid
mimic
diii
stem
region
prepar
proven
block
andv
puuv
infect
vero
cell
block
membran
fusion
barriga
et
al
strategi
use
viral
gc
diii
stem
fragment
suppress
fusion
might
feasibl
hantavirus
protect
effect
vivo
still
need
studi
confirm
furthermor
antivir
target
hantavir
receptor
synthes
demonstr
pathogen
hantavirus
attach
cell
surfac
via
hostspecif
iib
v
integrin
nonpathogen
hantavirus
initi
cellular
entri
reli
v
integrin
jiang
et
al
base
structur
cyclic
peptid
known
bind
v
receptor
cyclic
peptid
small
molecul
design
screen
antihantavir
function
cyclic
nonapeptid
clvrnlawc
cqattarnc
could
inhibit
snv
andv
infect
vitro
hall
et
al
two
round
biolog
screen
peptidomimet
compound
screen
potenc
nanomolar
rang
infect
panel
hantavirus
includ
snv
andv
htnv
hall
et
al
studi
perform
evalu
safeti
efficaci
small
molecul
vivo
viral
protein
work
molecul
viral
biosynthesi
among
rdrp
play
import
role
hantavir
transcript
replic
consid
desir
drug
target
pyrazin
deriv
favipiravir
nucleosid
analog
ribavirin
rbv
etar
test
effect
antihantavir
drug
directli
indirectli
affect
biolog
function
rdrp
favipiravir
avigan
initi
discov
antivir
drug
select
inhibit
rdrp
influenza
viru
report
high
activ
panel
bunyavirus
gowen
et
al
westov
et
al
favipiravir
could
attenu
viral
rna
replic
level
decreas
progeni
viru
yield
snv
andv
vitro
vivo
studi
includ
nonleth
snv
challeng
lethal
andv
challeng
hamster
model
demonstr
oral
administr
favipiravir
dosag
mgkg
twice
daili
could
promin
reduc
viral
load
hamster
serum
variou
organ
result
surviv
andv
lethal
infect
model
safronetz
et
al
delay
favipiravir
administr
onset
viremia
exert
protect
effect
andv
infect
notabl
report
clinic
trial
favipiravir
antivir
treatment
hfr
hcp
rbv
etar
nucleosid
analog
interfer
viral
replic
inhibit
inosin
monophosph
dehydrogenas
reduc
synthesi
gtp
de
novo
henc
affect
function
viral
rdrp
potent
mutagen
rbv
could
induc
rna
mutagenesi
subsequ
gener
htnv
virion
chung
et
al
expect
etar
induc
mutat
probabl
due
lack
pseudobas
pair
presenc
chung
et
al
addit
rbv
report
modul
host
immun
respons
suppress
regulatori
cell
kobayashi
et
al
evid
show
etar
could
exert
immunoregulatori
effect
szabo
vitro
vivo
antihantavir
activ
rbv
etar
confirm
seri
studi
hfr
therapi
rbvtreat
suckl
mice
higher
surviv
rate
upon
htnv
infect
placebo
control
group
huggin
et
al
china
doubleblind
placebocontrol
clinic
trial
enrol
hfr
patient
caus
htnv
infect
result
show
postexposur
administr
rbv
could
decreas
mortal
sevenfold
reduc
risk
enter
oligur
phase
suggest
rbv
effect
htnvinduc
hfr
huggin
et
al
howev
clinic
trial
hfr
caus
puuv
infect
russia
show
rbv
could
improv
patient
condit
especi
reduc
viral
load
rbv
could
increas
occurr
side
effect
rbv
includ
rash
sinu
bradycardia
hyperbilirubinemia
reduc
hemoglobin
data
suggest
insuffici
efficaci
safeti
rbv
treatment
hfr
caus
puuv
malinin
platonov
hcp
treatment
two
studi
confirm
rbv
could
protect
hamster
lethal
intraperiton
intranas
andv
challeng
without
toxic
even
abbrevi
treatment
regimen
day
day
work
therapi
commenc
day
follow
viru
challeng
safronetz
et
al
ogg
et
al
unfortun
two
clinic
trial
treatment
hcp
use
rbv
show
improv
surviv
rate
compar
patient
time
frame
receiv
placebo
treatment
specul
rbv
treatment
might
ineffect
hcp
progress
cardiopulmonari
phase
etar
show
ec
valu
htnv
andv
vero
cell
respect
much
lower
toxic
dosag
chung
et
al
moreov
etar
administr
suck
mice
dosag
mgkg
day
post
htnv
infect
could
significantli
increas
surviv
rate
effect
equal
rbv
chung
et
al
date
studi
antivir
activ
etar
hantavirus
hantavir
np
could
bind
evolutionari
conserv
sequenc
terminu
hantavir
genom
rna
interact
np
viral
genom
could
protect
viral
rna
host
recognit
degrad
facilit
nmediat
viral
rna
translat
process
help
packag
viral
genom
nucleocapsid
sever
compound
name
lead
inhibitor
report
interrupt
nprna
interact
snv
andv
infect
could
abrog
viral
rna
synthesi
translat
without
affect
normal
biolog
process
host
cell
among
show
antivir
activ
similar
rbv
salim
et
al
howev
fail
affect
replic
hiv
adenoviru
demonstr
select
hantavirus
arbidol
immunomodul
develop
russia
also
found
protect
htnv
infect
vivo
vitro
deng
et
al
target
viral
rna
direct
effect
way
curb
hantavir
replic
small
interf
rna
sirna
direct
hantavir
gene
could
facilit
viral
rna
clearanc
base
rna
interf
rnai
mechan
test
potenti
antivir
strategi
vitro
vivo
demonstr
sirna
target
l
segment
andv
could
reduc
viral
replic
vero
cell
human
lung
microvascular
endotheli
cell
starget
sirna
pool
seem
effici
reduc
viral
transcript
replic
mor
ltarget
sirna
vero
cell
importantli
sirna
could
inhibit
andv
replic
even
given
infect
chiang
et
al
although
sirna
could
effect
suppress
hantaviru
amplif
host
cell
like
promot
viral
rna
clearanc
antivir
activ
might
greatli
compromis
consid
poor
biolog
stabil
target
abil
vivo
one
strategi
combin
sirna
target
encod
sequenc
htnv
genom
recombin
antibodi
recogn
htnv
gc
appli
intraperiton
inject
htnvinduc
enceph
mous
model
result
indic
combin
sirna
could
specif
deliv
htnvinfect
brain
cell
protect
htnv
intracrani
infect
account
novel
deliveri
system
develop
ensur
stabil
select
sirna
efficaci
safeti
system
remain
unclear
treatment
hfr
hcp
increas
capillari
leakag
due
hantavir
infect
basic
pathogen
featur
hfr
hcp
therefor
treatment
strategi
improv
microvascular
endotheli
cell
function
seem
feasibl
mitig
diseas
sever
reduc
mortal
alkharsah
hantavirusdisturb
vascular
function
multifactori
event
whose
complic
mechan
still
need
elucid
two
kind
hypothesi
develop
vascular
endotheli
growth
factor
vegf
theori
first
propos
studi
depth
vegf
bind
vegf
receptor
could
activ
sfk
src
famili
kinas
signal
may
result
dissoci
intern
degrad
vecadherin
alter
express
local
vecadherin
contribut
impair
barrier
structur
adher
junction
could
lead
increment
cellular
permeabl
jiang
et
al
demonstr
htnv
andv
infect
could
disrupt
interact
integrin
induc
hyper
phosphoryl
may
enhanc
permeabl
infect
endotheli
cell
sensit
vegf
gavrilovskaya
et
al
wang
et
al
increas
vegf
content
note
plasma
hfr
hcp
patient
close
relat
diseas
sever
acut
phase
bird
et
al
pal
et
al
feasibl
repurpos
fdaapprov
drug
target
vasoact
mediat
use
hantavir
infect
therapi
line
strategi
one
studi
report
kinas
inhibitor
well
sfk
inhibitor
could
obvious
stabil
andvinduc
endovascular
permeabl
among
sfk
inhibitor
dasatinib
pazopanib
block
vecadherin
dissoci
gorbunova
et
al
anoth
studi
also
indic
applic
vandetanib
tyrosinekinas
inhibitor
prevent
phosphoryl
andv
infect
could
delay
anim
lethal
increas
total
surviv
andvchalleng
hamster
bird
et
al
contrast
similar
small
molecul
administ
onset
viremia
fail
protect
hamster
lethal
andv
challeng
brocato
hooper
moreov
small
molecul
angiopoietin
sphingosin
found
inhibit
hantavirusdirect
endotheli
cell
permeabl
vitro
gavrilovskaya
et
al
research
vivo
perform
confirm
efficaci
anoth
promis
theori
increas
activ
kininkallikrein
system
kk
hantaviru
infect
one
studi
use
model
cocultur
endotheli
vascular
smooth
muscl
cell
demonstr
activ
kk
subsequ
liber
bradykinin
bk
vegf
mainli
respons
dramat
increas
endotheli
cell
permeabl
hantaviru
infect
taylor
et
al
bk
nonapeptid
bind
bk
type
receptor
could
induc
blood
vessel
dilat
vascular
permeabl
increas
result
collaps
blood
pressur
icatib
peptidomimet
drug
block
interact
bk
bk
type
receptor
bind
receptor
one
case
report
male
underw
splenectomi
due
congenit
spherocytosi
manifest
sever
capillari
leakag
syndrom
caus
puuv
infect
singl
dose
icatib
condit
patient
stabil
follow
gradual
improv
full
recoveri
antonen
et
al
anoth
case
report
also
confirm
effici
treatment
icatib
femal
hfr
patient
lain
et
al
clinic
data
indic
bk
receptor
antagonist
might
novel
treatment
strategi
hantaviru
diseas
nevertheless
also
note
foresaid
two
patient
spleen
abnorm
might
relat
cur
effect
icatib
clinic
trial
enrol
larg
number
hfr
hcp
patient
perform
identifi
remedi
effect
bradykinin
receptor
antagonist
wildli
accept
hfr
hcp
caus
uncontrol
system
inflammatori
respons
multipl
inflammatori
cytokin
especi
rant
contribut
diseas
progress
manigold
vial
schonrich
rafteri
howev
immunoregul
treatment
hfr
hcp
undesir
recent
studi
deplet
alveolar
macrophag
consid
main
resourc
proinflammatori
respons
could
prevent
andvcaus
pathogenesi
hamster
hammerbeck
et
al
immunomodulatori
treatment
corticoid
firstli
perform
korean
war
case
fatal
rate
improv
sayer
et
al
chile
retrospect
analysi
suggest
high
dose
methylprednisolon
could
reduc
mortal
hcp
patient
brocato
hooper
howev
doubleblind
clinic
trial
chile
fail
observ
significantli
improv
outcom
methylprednisolon
recipi
placebo
recipi
hcp
similarli
anoth
random
prospect
studi
show
benefit
corticosteroid
treatment
hfr
patient
qian
et
al
initi
care
observ
prompt
judici
support
treatment
crucial
improv
patient
surviv
condit
hfr
hcp
sargian
et
al
demonstr
admiss
icu
support
treatment
could
greatli
reduc
mortal
rate
hfr
huggin
et
al
gener
treatment
principl
hfr
patient
use
intraven
hydrat
electrolyt
therapi
maintain
physiolog
blood
pressur
platelet
transfus
appli
reduc
mortal
patient
sever
thrombocytopenia
intermitt
hemodialysi
ihd
first
choic
improv
uremia
condit
rectifi
kidney
dysfunct
patient
acut
kidney
injuri
continu
renal
replac
therapi
crrt
appli
critic
hfr
patient
especi
complic
multiorgan
injuri
pulmonari
edema
cerebropathi
jiang
et
al
treatment
patient
hcp
also
perform
icu
continu
cardiac
monitor
respiratori
support
palli
treatment
hcp
usual
includ
mechan
ventil
extracorpor
membran
oxygen
hemofiltr
sargian
et
al
hfr
hcp
caus
hantaviru
infect
reemerg
infecti
diseas
greatli
threaten
global
public
health
present
current
us
fdaapprov
treatment
vaccin
avail
whole
virusinactiv
vaccin
htnv
seov
avail
china
korea
implement
intervent
measur
incid
hantaviru
infect
seem
shown
declin
recent
year
china
korea
number
hfr
case
drastic
reduc
vaccin
elicit
suboptim
immun
respons
confer
inadequ
protect
may
caus
safeti
concern
recurr
global
outbreak
hfr
drawn
renew
attent
old
diseas
serious
threaten
human
health
hfr
china
still
natur
focal
diseas
rel
high
morbid
fatal
distribut
epidem
trend
also
chang
surveil
measur
togeth
prevent
control
strategi
improv
strengthen
reduc
hfr
infect
china
therefor
best
solut
develop
function
vaccin
prevent
hantaviru
infect
among
three
type
vaccin
discuss
dna
vaccin
candid
progress
clinic
trial
subunit
protein
vaccin
safe
easi
produc
also
easili
caus
interfer
compon
multival
formul
liang
et
al
qu
et
al
resolv
problem
propos
construct
univers
genet
engin
novel
subunit
protein
vaccin
htnv
seov
combin
bioinformat
method
viral
surfac
protein
structur
biolog
knowledg
molecular
biolog
tool
antivir
treatment
work
appli
earli
infect
stage
possibl
uncontrol
immun
respons
occur
predomin
pathogenesi
process
postacut
infect
immunomodulatori
therapi
hardli
improv
patient
surviv
rate
possibl
suppress
inflammatori
respons
inhibit
prompt
viral
clearanc
enhanc
viruscaus
injuri
increas
therefor
base
rapid
support
care
effect
combin
antivir
treatment
immunomodulatori
therapi
potenti
strategi
hfr
hp
mice
mab
htnv
develop
team
use
hfr
treatment
result
indic
applic
earli
stage
diseas
could
significantli
improv
patient
condit
increas
surviv
rate
especi
sever
critic
hfr
patient
data
unpublish
henc
nab
might
promis
treatment
hfr
hp
effect
human
neutral
antibodi
develop
moreov
univers
acknowledg
type
ifn
respons
essenti
host
defend
hantavir
infect
multipl
ifn
stimul
gene
isg
confirm
antihantavir
activ
interferoninduc
mxa
protein
gtpase
extens
antivir
activ
notabl
influenza
virus
report
inhibit
htnv
puuv
replic
vero
cell
frese
et
al
interferoninduc
protein
abl
inhibit
htnv
infect
huvec
cell
inhibit
viru
entri
xuyang
et
al
sever
studi
shown
pretreat
type
ifn
could
effect
inhibit
hantavir
infect
pretreat
endotheli
cell
ec
block
hantaviru
replic
inhibitori
effect
still
observ
ad
ec
within
hpi
howev
addit
h
infect
littl
effect
hantaviru
replic
clinic
data
indic
ifn
treatment
effect
prophylact
shortli
hantaviru
infect
fact
natur
infect
process
compar
nonpathogen
hantavirus
pathogen
hantavirus
could
inhibit
host
ifn
product
earli
infect
stage
specif
mechan
remain
ambigu
team
recent
found
htnv
could
induc
complet
autophagi
earli
phase
promot
host
mav
degrad
disturb
rigimav
signalingmedi
ifn
product
applic
autophagi
inhibitor
includ
cq
could
significantli
enhanc
type
ifn
respons
inhibit
htnv
replic
vitro
vivo
also
demonstr
lncrna
could
posit
regul
ifn
respons
htnv
infect
overexpress
could
restrain
htnv
amplif
vitro
vivo
result
suggest
enhanc
host
ifn
respons
earli
infect
phase
may
novel
therapeut
strategi
hfr
hcp
still
much
work
done
translat
basic
medicin
research
clinic
practic
